| Title |
Diagnosis and Management of Autoimmune Myasthenia Gravis
|
|---|---|
| Published in |
Clinical Drug Investigation, August 2012
|
| DOI | 10.2165/11584740-000000000-00000 |
| Pubmed ID | |
| Authors |
Corrado Angelini |
| Abstract |
Earlier diagnosis and the availability of effective treatments have reduced the burden of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much improved. However, despite extensive knowledge of MG and its aetiology, diagnosing the disease remains problematic and can be delayed because of its nonspecific and fluctuating symptoms, and the management of MG is associated with considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from prolonged immune suppression. There is a need for improved awareness among primary caregivers about this relatively rare, but treatable, disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 2% |
| Unknown | 47 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 21% |
| Student > Ph. D. Student | 6 | 13% |
| Student > Postgraduate | 6 | 13% |
| Other | 3 | 6% |
| Professor | 3 | 6% |
| Other | 8 | 17% |
| Unknown | 12 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 50% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Neuroscience | 2 | 4% |
| Psychology | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 12 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 April 2014.
All research outputs
#17,286,645
of 25,374,917 outputs
Outputs from Clinical Drug Investigation
#770
of 1,035 outputs
Outputs of similar age
#124,145
of 186,743 outputs
Outputs of similar age from Clinical Drug Investigation
#313
of 344 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,035 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,743 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 344 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.